Research progress on anti-tumor drug resistance of pyridazine-containing structural compounds.

Pyridazine is an aromatic heterocyclic organic compound with a six-membered ring containing four carbon and two nitrogen atoms. Studies have demonstrated their multiple pharmacological properties, including anticancer, antiviral, and anti-Parkinson's disease effects. Recently, there has been increasing interest in their potential anti-tumor resistance activity. Several pyridazine-based drugs and their analogs are currently undergoing clinical trials at different stages, suggesting that pyridazine is a promising chemical structure for drug development. Notably, modifications of pyridazine structures significantly affect their anti-tumor resistance activity. This review summarizes current advances in developing pyridazine derivatives as anti-tumor drug, highlighting key SAR-based design optimization strategies, molecular design principles, and mechanistic insights into target binding. These insights could pave the way for the development of more effective anti-tumor agents overcoming resistance.